| 4 | 2023 | 年 | 10 | 四届 | 《关于公司 2023 年第三季度报告的议案》 | 全部 | | --- | --- | --- | --- | --- | --- | --- | | | 月 | 25 | 日 | 二十次 | | 通过 | | 5 | 2023 | 年 | 12 | 四届 二十一 | 《关于续聘会计师事务所的议案》 | 全部 | | | 月 | 8 | 日 | | | 通过 | | | | | | 次 | | | 葵花药业集团股份有限公司 2023 年度监事会工作报告 2023 年度，葵花药业集团股份有限公司（以下简称"公司"）监事会严格 按照《公司法》、《证券法》、《公司章程》以及《监事会议事规则》的有关规 定，依法独立行使监事会监督职权，对公司及全体股东负责。 公司监事会成员 3 人，均能够积极履行监事职责，出席或列席历次股东大会、 董事会会议，依法召开监事会会议，审议各项议案，对公司生产经营、财务状况、 关联交易及董事、高级管理人员履职情况等方面进行有效的监督。监事会成员中， 职工代表监事兰芬女士、监事何岩女士在公司兼任相关管理岗位，在日常履行管 理岗位职能过程中， ...

葵花药业集团股份有限公司 董事、监事人员薪酬方案 一、董事、监事 2023 年度薪酬确认 根据《公司章程》及相关薪酬管理制度的规定，公司对相关人员薪酬情况进 行了考核与确认。具体详见公司 2023 年年度报告第四节-公司治理-五、董事、 监事和高级管理人员-3、董事、监事、高级管理人员报酬情况。 二、董事、监事 2024 年度薪酬（津贴）方案 3、其他非独立董事 （1）未在本公司控股股东、本公司（含子公司）担任管理层职务：采用固 定津贴制，津贴标准为 5 万元/年。 （一）适用期限 董事、监事薪酬（津贴）自公司股东大会审议通过之日起生效，至股东大会 审议通过新的董事、监事薪酬（津贴）方案之日止。 （二）适用对象 在公司领取薪酬的董事、监事。 （三）具体方案 1、独立董事 采用固定津贴制，津贴标准为 6 万元/年。 2、董事长 董事长：采用年薪制，年薪=基本年薪+绩效奖金，基本年薪按月发放，绩效 奖金结合公司年度经营指标、年度绩效考核完成情况等因素综合评定后统一发放。 根据《上市公司治理准则》及《公司章程》等相关规定，结合公司实际情况 及所处行业情况，公司拟定 2024 年度董事、监事人员薪酬方案如下： （2） ...

根据《 上市公司独立董事管理办法》、 深圳证券交易所上市公司自律监管指 引第 1 号——主板上市公司规范运作》、 葵花药业集团股份有限公司章程》（以 下简称"《 公司章程》"）及 葵花药业集团股份有限公司独立董事工作制度》等 相关规定，并结合独立董事出具的 独立董事关于独立性自查情况的报告》，葵 花药业集团股份有限公司（以下简称"公司"）董事会就公司在任独立董事施先 旺先生、林瑞超先生、崔丽晶女士的独立性情况进行评估并出具如下专项意见： 经对独立董事施先旺先生、林瑞超先生、崔丽晶女士任职经历以及签署的相 关自查文件进行核查，上述人员未在公司担任除独立董事以外的任何职务，也未 在公司主要股东公司担任任何职务，与公司以及主要股东之间不存在利害关系或 其他可能妨碍其进行独立客观判断的关系，不存在影响独立董事独立性的情况， 符合 上市公司独立董事管理办法》 深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》中对独立董事独立性的相关要求。 葵花药业集团股份有限公司 关于独立董事独立性自查情况的专项报告 《《《《《《《《《《《《《《《《《《《《《《《《《《《《《《《《《《《《《《《《《《《《《《《《《 ...

葵花药业集团股份有限公司 2023 年度内部控制自我评价报告 葵花药业集团股份有限公司 2023 年度内部控制自我评价报告 葵花药业集团股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求 （以下简称企业内部控制规范体系），结合葵花药业集团股份有限公司（以下简称 "公司"或"本公司"）内部控制制度和评价办法，在内部控制日常监督和专项监 督的基础上，我们对公司 2023 年 12 月 31 日（内部控制评价报告基准日）的内部 控制有效性进行了评价。 一、重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有 效性，并如实披露内部控制自我评价报告是公司董事会的责任。监事会对董事会建 立和实施内部控制进行监督。经理层负责组织、领导企业内部控制的日常运行。公 司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存在任何虚假记 载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别及 连带法律责任。 公司内部控制的目标：合理保证经营合法合规、资产安全、财务报告及相关信 息真实完整，提高经营效率与效果，促进发展战略的实现。由于内部控制存 ...

葵花药业集团股份有限公司 2023 年度独立董事述职报告 一、 出席会议情况 1、股东大会、董事会 （林瑞超） 本人作为葵花药业集团股份有限公司（以下简称"公司"或"本公司"）的 独立董事，2023 年严格按照《公司法》、《上市公司独立董事管理办法》、《公 司章程》等相关法律法规和规章制度的规定和要求，勤勉尽责地履行独立董事职 责，对公司经营发展提供建议，对潜在的利益冲突事项进行监督，维护公司和全 体股东特别是中小股东的合法权益。 现将 2023 年度本人履职情况报告如下： 同时，本人作为第四届董事会薪酬与考核委员会召集人、战略委员会委员， 严格按照公司《董事会薪酬与考核委员会工作细则》、《董事会战略委员会工作 细则》等相关制度的规定，审议董事、高级管理人员薪酬方案，结合外部环境、 2、董事会专门委员会 行业政策就公司战略与管理层进行交流，审议公司 2023 年度发展战略，建议公 司关注中成药集采政策，结合企业实际需求参与中药集采并被公司采纳，发挥了 专门委员会的职能与作用。 | | 战略委员会 | | 薪酬与考核委员会 | | | --- | --- | --- | --- | --- | | 林瑞超 | ...

证券代码：002737 证券简称：葵花药业 公告编号：2024-016 葵花药业集团股份有限公司 关于举行 2023 年度网上业绩说明会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 葵花药业集团股份有限公司（以下简称"公司"）于 2024 年 4 月 26 日披露 公司 2023 年年度报告。为便于广大投资者更加深入、全面的了解公司年度经营 情况，公司定于 2024 年 5 月 14 日（星期二）15：00–17：00 在全景网举办 2023 年度网上业绩说明会，本次年度业绩说明会将采用网络远程的方式举行，投资者 可登陆全景网"投资者关系互动平台"（http://ir.p5w.net）参与本次年度业绩 说明会。 出席本次年度网上业绩说明会的人员有：公司董事长关玉秀女士、独立董事 施先旺先生，公司副总经理海洋先生、财务负责人吴春红女士、董事会秘书周广 阔先生。 为提升本次交流的针对性，现就本次年度业绩说明会提前向投资者公开征集 问题，投资者可提前访问(https://ir.p5w.net/zj/)，或扫描下方二维码，进入 问题征集专题页面。公司将在本次 ...

二○二三年度 葵花药业集团股份有限公司 审计报告及财务报表 （2023 年 01 月 01 日至 2023 年 12 月 31 日止） | | 目录 | 页次 | | --- | --- | --- | | 一、 | 审计报告 | 1-5 | | 二、 | 财务报表 | | | | 合并资产负债表和母公司资产负债表 | 1-4 | | | 合并利润表和母公司利润表 | 5-6 | | | 合并现金流量表和母公司现金流量表 | 7-8 | | | 合并所有者权益变动表和母公司所有者权益变动表 | 9-12 | | | 财务报表附注 | 1-124 | 审计报告 葵花药业集团股份有限公司 审计报告及财务报表 我们审计了葵花药业集团股份有限公司（以下简称葵花药业）财 务报表，包括 2023 年 12 月 31 日的合并及母公司资产负债表，2023 年度的合并及母公司利润表、合并及母公司现金流量表、合并及母公 司所有者权益变动表以及相关财务报表附注。 我们认为，后附的财务报表在所有重大方面按照企业会计准则的 规定编制，公允反映了葵花药业 2023 年 12 月 31 日的合并及母公司 财务状况以及 2023 年度的合 ...

证券代码：002737 证券简称：葵花药业 公告编号：2024-012 葵花药业集团股份有限公司 关于会计政策变更的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 葵花药业集团股份有限公司（以下简称"公司"或"本公司"）于 2024 年 4 月 25 日召开第四届董事会第二十九次会议和第四届监事会第二十二次会议， 审议通过了《关于会计政策变更的议案》，同意根据相关法律、法规及规范性文 件要求，执行新的会计政策。具体情况如下： 根据财政部相关准则及通知规定，上述事项自 2023 年 1 月 1 日起施行。 （二）变更前后采用的会计政策 1、变更前采用的会计政策 本次变更前，公司执行财政部发布的《企业会计准则—基本准则》及各项具 体会计准则、企业会计准则应用指南、企业会计准则解释公告及其他相关规定。 2、变更后采用的会计政策 本次会计政策变更后，公司将按照财政部发布的准则解释 16 号的要求执行。 除上述会计政策变更外，其他未变更部分，仍按照财政部前期颁布的《企业会计 1 一、本次会计政策变更概述 （一）会计政策变更的原因及变更日期 1、变更原因 2022 ...

Financial Performance - The company's operating revenue for 2023 reached ¥5,700,286,745.90, representing an increase of 11.89% compared to the previous year[27]. - Net profit attributable to shareholders for 2023 was ¥1,119,142,042.33, marking a 29.05% increase year-over-year[27]. - The net profit after deducting non-recurring gains and losses was ¥1,003,471,054.23, up 24.77% from the previous year[27]. - Basic earnings per share for 2023 were ¥1.92, a 29.73% increase compared to ¥1.48 in 2022[27]. - The total assets at the end of 2023 were ¥6,881,912,554.92, a decrease of 2.13% from the previous year[27]. - Net assets attributable to shareholders increased by 13.29% to ¥4,763,440,300.18 at the end of 2023[27]. - The company reported total assets of 688,191.26 million CNY and net assets attributable to shareholders of 476,344.03 million CNY as of the end of 2023[67]. - The company reported a sales volume of 816,798,369 boxes in 2023, representing a year-on-year increase of 7.21% compared to 2022[105]. - The production volume for 2023 was 880,196,479 boxes, reflecting a significant year-on-year growth of 21.03%[105]. - The company's inventory increased dramatically by 234.37% year-on-year, reaching 90,449,002 boxes in 2023[105]. Dividend and Shareholder Returns - The company plans to distribute a cash dividend of 15 RMB per 10 shares to all shareholders based on a total share capital of 584,000,000 shares as of December 31, 2023[16]. Strategic Focus and Market Position - The company aims to enhance its focus on traditional Chinese medicine, aligning with national policies to promote its development[35]. - The company aims to strengthen its leading position in the OTC market while increasing investment in advanced business models in the pharmaceutical and health sectors[59]. - The company is focused on expanding its market presence through both internal growth and external investments, aiming to unlock user, brand, channel, and investment value[58]. - The company is committed to enhancing its brand value and user experience through high-quality products and integrity in operations[61]. - The company is enhancing its product structure and adopting a proactive approach to research and development to capture emerging market segments[184]. Risks and Challenges - The company faces risks including market competition, raw material price fluctuations, and potential underperformance of new products[39]. - The company is addressing risks related to policy changes in the pharmaceutical industry, raw material price fluctuations, and new product introduction failures by enhancing internal controls and optimizing business structures[161][162]. - The company recognizes risks related to market competition and fluctuations in raw material prices, and it is actively monitoring these factors to mitigate potential impacts on profitability[183][184]. Research and Development - Research and development investment rose to 128,647,229.20 yuan in 2023, a 35.97% increase from 2022, accounting for 2.26% of operating revenue[113]. - The company is actively developing 36 functional food projects, emphasizing its commitment to health and wellness products[69]. - The company has a total of 1,126 drug approval numbers, with 555 included in the national medical insurance directory and 283 in the national essential drug list, indicating a strong product portfolio[87]. - The company is expanding its product pipeline through mergers, independent research and development, and partnerships, enhancing its competitive edge in the pharmaceutical market[87]. Operational Efficiency - The company aims to enhance operational efficiency and resource allocation through improved financial management and digitalization efforts[74]. - The company is focusing on cost control through strategic reserves and optimizing production processes to mitigate the impact of rising raw material prices[73]. - The company is committed to optimizing its total cost structure by selecting raw materials carefully and improving production processes to ensure cost efficiency[182]. Brand and Marketing Strategies - The company has implemented a new media communication strategy in 2023, enhancing brand exposure and customer engagement through various promotional activities[72]. - The company aims to enhance brand recognition and drive online growth through user-centric strategies and effective product management[145]. - The company is leveraging digitalization and AI to enhance its marketing strategies and drive growth in the traditional pharmaceutical industry[159]. Corporate Governance and Compliance - The company is committed to continuous improvement in corporate governance and compliance with regulatory requirements[167]. - The company emphasizes the importance of a robust compliance system and organizational development to support sustainable growth[182]. Community Engagement - The company has committed over 11 million yuan in social donations in 2023, including more than 8 million yuan in cash donations[122].

Financial Performance - The company's operating revenue for the current period is ¥1,518,181,069.65, a decrease of 14.01% compared to the same period last year[6] - The net profit attributable to shareholders for the current period is ¥255,183,288.86, down 37.17% year-over-year[6] - The net profit after deducting non-recurring gains and losses is ¥237,454,340.04, reflecting a decline of 39.18% compared to the previous year[6] - The basic earnings per share for the current period is ¥0.44, a decrease of 37.14% from ¥0.70 in the same period last year[6] - The total operating revenue for the first quarter of 2024 was ¥1,518,181,069.65, a decrease of approximately 14.0% compared to ¥1,765,521,894.46 in the same period last year[26] - The net profit attributable to shareholders of the parent company was ¥255,206,220.86, down from ¥406,131,973.46, representing a decrease of about 37.1%[28] - The basic and diluted earnings per share for the first quarter were both ¥0.44, compared to ¥0.70 in the same period last year, a decline of approximately 37.1%[28] - Net profit decreased by 37.91% to ¥270,303,238.96 compared to ¥435,364,881.11 in the previous period, primarily due to a decline in revenue and increased costs from rising Chinese medicinal material prices[44] Assets and Equity - The total assets at the end of the current period amount to ¥7,146,595,311.44, representing a 3.85% increase from the end of the previous year[6] - The equity attributable to shareholders at the end of the current period is ¥5,021,155,795.83, which is a 5.41% increase compared to the previous year[6] - The total current assets increased to ¥5,087,394,714.11 from ¥4,787,964,197.21, reflecting an increase of approximately 6.3%[24] - The cash and cash equivalents at the end of the period were ¥3,496,677,467.15, up from ¥2,287,009,419.54, representing an increase of about 53.0%[24] - The inventory balance increased to ¥909,915,396.70 from ¥873,189,831.01, showing an increase of approximately 4.2%[24] - The total assets increased to ¥7,146,595,311.44 from ¥6,881,912,554.92, reflecting a growth in overall asset base[43] Cash Flow - The net increase in cash and cash equivalents for the current period is ¥1,209,972,261.26, compared to ¥451,842,275.99 in the previous year[3] - The cash flow from operating activities for the current period is ¥204,290,572.95, down 17.97% from the previous year[6] - The net cash flow from operating activities was ¥204,290,572.95, compared to ¥249,028,652.64 in the previous year, indicating a decline of approximately 17.9%[30] - Cash inflow from investment activities totaled ¥1,020,817,239.73, significantly higher than ¥252,569,927.27 in the previous year[30] - The cash outflow for purchasing fixed assets and intangible assets was ¥13,985,381.42, compared to ¥36,350,120.38 in the previous year, indicating a decrease of about 61.6%[30] - Investment activities generated a net cash flow of ¥1,006,831,858.31, a significant increase of 413.11% from ¥196,219,806.89 in the previous period, mainly due to the redemption of maturing financial products[44] - Cash and cash equivalents increased by 52.89% to ¥3,496,677,467.15 from ¥2,287,009,419.54, primarily due to the redemption of financial products during the period[50] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 32,355[52] - The largest shareholder, KuaHua Group Co., Ltd., holds 45.41% of the shares, totaling 265,200,000 shares[52] - The second-largest shareholder, Guan Yanbin, holds 6.03% of the shares, totaling 35,220,422 shares[52] - The company has not engaged in margin trading or securities lending activities by its controlling shareholders or related parties[52] Government Support and Other Income - The company received government subsidies amounting to ¥22,444,571.68 during the current period[18] - Other income rose by 42.22% to ¥23,156,203.91, primarily due to government subsidies received in the current period[44] Operational Developments - The company has made progress in product development, including the approval of a new oral suspension product[23] - The report indicates a focus on financial product management and revenue recognition strategies for future growth[50] - The company is exploring market expansion opportunities and potential mergers and acquisitions to enhance its competitive position[50] Financial Management - Financial expenses decreased by 99.69% to -¥11,113,152.12, attributed to an increase in bank interest income during the current period[44] - Credit impairment losses increased by 82.60% to -¥2,991,054.06, mainly due to provisions for bad debts[44] - The company reported a 272.37% increase in operating expenses to ¥938,184.74, primarily due to external donation expenditures[44] - The fair value change in investment income showed a significant increase of 98.35%, reaching ¥5,407,601.03, attributed to returns from financial products[44] - The cash flow from financing activities decreased by 115.39% to -¥1,015,792.56, primarily due to the absence of bank borrowings in the current period[44] Liabilities and Receivables - Trading financial assets decreased by 77.18% to ¥300,159,000.00 from ¥1,315,104,600.00, also attributed to the redemption of financial products[50] - Accounts receivable financing rose by 157.57% to ¥92,248,199.27 from ¥35,814,204.43, mainly due to an increase in collected notes[50] - Contract liabilities decreased by 47.21% to ¥156,972,360.41 from ¥297,324,795.11, primarily due to revenue recognition based on performance obligations[50]